Search, Look, and See; Late Recognised Hypereosinophilic Syndrome with Deletion (4) (q12)-Reference-Cited by-同舟云学术

Search, Look, and See; Late Recognised Hypereosinophilic Syndrome with Deletion (4) (q12)

Published:2023-06-15 Issue:2 Volume:13 Page:441-443
ISSN:2459-1459
Container-title:Clinical and Experimental Health Sciences
language:
Short-container-title:

Author:

BUYUKKURT Nurhilal¹^ORCID,PEPEDİL TANRİKULU Funda²^ORCID

Affiliation:

1. Baskent University Faculty of Medicine, Internal Medicine, Department of Hematology, Ankara, Turkey

2. Department of Hematology, Adana City Hospital, Adana

Abstract

The hypereosinophilic syndrome (HES) is a group of rare disorders characterized by persistently high peripheral blood eosinophiles (≥ 1.5x109/L), and related signs or symptoms of organ involvement without secondary causes. Eosinophilia with recurrent genetic abnormalities (PDGFRA/B, FGFR1) comprises a minority of these patients. In this report, we aimed to point out a case with 4q12 deletion whose diagnosis and treatment were delayed for quite a while. The patient was followed for bronchial asthma for a long time and the recognition of hypereosinophilia yielded a suspicion for HES / Chronic eosinophilic leukemia (CEL). During the initial part of his diagnostic evaluation, there was an unawareness of the cryptic deletion which was a target for tyrosine kinases. The symptoms resolved and complete cytogenetic response was achieved with 100 mg imatinib continuing for 57 months.

Publisher

Marmara University

Subject

General Materials Science

Reference15 articles.

1. Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015 Aug 27;126(9):1069-1077.

2. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, Erben P, Popp H, Walz C, Hochhaus A, Roche-Lestienne C, Preudhomme C, Apperley J, Rondoni M, Ottaviani E, Martinelli G, Finella Brito-Babapulle, Saglio G, Hehlmann R, C P Cross N, Reiter A, Grimwade D. Low-dose imatinib mesylate leads to rapid inductionof major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007;109:4635–4640.

3. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling, Lasho TL, Ho C-L, Li C-Y, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038–3045.

4. Pardanani A, Ketterling RP, Li CY, Patnaik M M, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A. FIP1L1-PDGFRA in eosinophilic disorders:Prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965–970.

5. Brigden M, Graydon C. Eosinophilia detected by automated blood cell counting in ambulatory North American outpatients. Incidence and clin-ical significance. Arch Pathol Lab Med. 1997;121:963-967.